MOMETASONE SUBSTIPHARM 50 microgrammes/dose, suspension pour pulvérisation nasale — 1 flacon(s) polyéthylène haute densité (PEHD) de 18 g (140 doses), avec pompe doseuse et applicateur nasal
Medicine package · Base de données publique des médicaments (BDPM), ANSM, HAS et Assurance Maladie · France
-
CIP13
3400930151341 -
CIP7
3015134 -
CIS
60877018
What the source publishes
- Holder
- SUBSTIPHARM
- Active ingredients
- FUROATE DE MOMÉTASONE, FUROATE DE MOMÉTASONE MONOHYDRATÉ
- Form
- suspension pour pulvérisation
- Package
- 1 flacon(s) polyéthylène haute densité (PEHD) de 18 g (140 doses), avec pompe doseuse et applicateur nasal
- Routes
- nasale
- Administrative status
- authorised
- Supply regime
- liste I
- Marketing status
- Déclaration de commercialisation
- Authorised on
- 2018-06-20
- Prescription
- Prescription or restricted
Names this record is found by
- MOMETASONE SUBSTIPHARM 50 microgrammes/dose, suspension pour pulvérisation nasale — 1 flacon(s) polyéthylène haute densité (PEHD) de 18 g (140 doses), avec pompe doseuse et applicateur nasal
- MOMETASONE SUBSTIPHARM 50 microgrammes/dose, suspension pour pulvérisation nasale
- FUROATE DE MOMÉTASONE
- FUROATE DE MOMÉTASONE MONOHYDRATÉ
Complete source data
{
"cis": "60877018",
"cip7": "3015134",
"form": "suspension pour pulvérisation",
"name": "MOMETASONE SUBSTIPHARM 50 microgrammes/dose, suspension pour pulvérisation nasale — 1 flacon(s) polyéthylène haute densité (PEHD) de 18 g (140 doses), avec pompe doseuse et applicateur nasal",
"cip13": "3400930151341",
"holder": "SUBSTIPHARM",
"routes": [
"nasale"
],
"holders": [
"SUBSTIPHARM"
],
"currency": "EUR",
"marketed": true,
"bdmStatus": null,
"useDomain": "unknown",
"publicPrice": "5.48",
"authorisedOn": "2018-06-20",
"compositions": [
{
"name": "FUROATE DE MOMÉTASONE",
"nature": "FT",
"strength": "50,00 microgrammes",
"linkageNumber": "1",
"substanceCode": "14446",
"dosageReference": "une dose délivrée",
"pharmaceuticalElement": "suspension"
},
{
"name": "FUROATE DE MOMÉTASONE MONOHYDRATÉ",
"nature": "SA",
"strength": null,
"linkageNumber": "1",
"substanceCode": "33681",
"dosageReference": null,
"pharmaceuticalElement": "suspension"
}
],
"sourceStatus": "Présentation active",
"supplyRegime": "liste I",
"dispensingFee": "1.02",
"medicinePrice": "4.46",
"regionalRules": "not-collected",
"targetSpecies": [],
"specialityName": "MOMETASONE SUBSTIPHARM 50 microgrammes/dose, suspension pour pulvérisation nasale",
"marketingStatus": "Déclaration de commercialisation",
"publicationDates": {
"CIS_bdpm": "2026-01-08",
"CIS_CIP_bdpm": "2026-11-19",
"CIS_CPD_bdpm": "2026-01-08",
"CIS_COMPO_bdpm": "2026-01-08"
},
"specialityListed": true,
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "fr.ansm.bdpm"
},
"collectiveApproval": "oui",
"packageDescription": "1 flacon(s) polyéthylène haute densité (PEHD) de 18 g (140 doses), avec pompe doseuse et applicateur nasal",
"patientEligibility": "not-assessed",
"reimbursementRates": [
"30 %"
],
"marketingDeclaredOn": "2019-04-17",
"targetSpeciesStatus": "not-reported",
"additionalMonitoring": false,
"administrativeStatus": "authorised",
"prescriptionCategory": "prescription-or-restricted",
"activeIngredientNames": [
"FUROATE DE MOMÉTASONE",
"FUROATE DE MOMÉTASONE MONOHYDRATÉ"
],
"authorisationProcedure": "Procédure décentralisée",
"prescriptionConditions": [
"liste I"
],
"reimbursementIndications": null,
"authorisationSourceStatus": "Autorisation active",
"europeanAuthorisationNumber": null,
"presentationAdministrativeStatus": "authorised"
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=fr" \
--data-urlencode "sourceId=fr.ansm.bdpm" \
--data-urlencode "id=fr:ansm:packages:3400930151341"